Most Recent
Neurim’s claim for additional damages survives in Circadin patent case
A judge has upheld Neurim Pharmaceutical’s claim for additional damages against two generic drug companies found to have infringed its patent for insomnia drug Circadin, despite the company's failure to comply with an earlier ruling.
After 7 years of litigation, patent for blockbuster sleep drug Circadin found valid
After a seven-year legal battle, a court has upheld the validity of Neurim Pharmaceutical’s patent for insomnia drug Circadin and ruled two generic drug companies infringed the intellectual property.
Zoetis can appeal Boehringer win over pig vaccine patents
US animal drug manufacturer Zoetis has been granted leave to appeal a ruling that invalidated three of its patents covering pig vaccines.
Court hands win to Boehringer in fight over Zoetis vaccine patents
German drug maker Boehringer has prevailed in its Federal Court fight against US rival Zoetis over the validity of three patents covering pig vaccines.
Novartis, Pharmacor resolve suit over Gilenya patents
Novartis and and generic drug maker Pharmacor have resolved litigation over the Swiss pharmaceutical giant's patents for blockbuster MS drug Gilenya.
Novartis can’t appeal loss of experts in MS drug patent feud with Pharmacor
The Full Federal Court won't give Swiss pharmaceuticals giant Novartis the chance to appeal a ruling that threw out three of its four experts in a patent case against generic drug maker Pharmacor.
Novartis challenges loss of experts in spat with Pharmacor over generic Gilenya
Novartis wants to appeal a ruling in its dispute with generic drug maker Pharmacor over patents for its multiple sclerosis drug Gilenya that tossed three of its four experts out of an upcoming so-called hot tub.
Judge tosses Novartis experts out of ‘hot tub’ in MS drug patent dispute
A judge has slammed Novartis for putting forward four "overlapping" experts in a dispute with Pharmacor over patents for its MS drug Gilenya and thrown three of those experts out of an upcoming joint conferral, known as a "hot tub".
Pharmacor challenges patent extension for Biogen’s MS drug
An Australian generic drug manufacturer has struck back at patent lawsuit by Swiss pharmaceutical company Biogen, alleging a patent for MS drug Tecfidera is invalid and a that a patent term extension for the drug  was wrongly granted.